Screener
Janux Therapeutics JANX Debt-to-equity
Debt-to-equity at other companies
Other financials
Where this comes from
Calculated from Janux Therapeutics’s reported figures.
Based on the most recent quarter.
The source filing: Janux Therapeutics’s 10-Q, filed August 6, 2026. Open the filing →
- Filed
- Aug 6, 2026, 4:18 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-338078
FAQ
- What is Janux Therapeutics's debt-to-equity?
- Janux Therapeutics (JANX) reported debt-to-equity of 0× in Q2 2026.
- How has Janux Therapeutics's debt-to-equity changed year-over-year?
- Janux Therapeutics's debt-to-equity increased by 0.9% year-over-year, from 0× to 0×.
- What is the long-term trend for Janux Therapeutics's debt-to-equity?
- Over 4 years (2021 to 2025), Janux Therapeutics's debt-to-equity has grown at a 160.7% compound annual growth rate (CAGR), from 0× to 0×.
- What does debt-to-equity mean?
- Total debt (including capitalized leases and financing obligations) divided by shareholders' equity at the quarter end. Measures how much the company is financed by debt relative to equity.
Ask your AI about Janux Therapeutics's debt-to-equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude